Atrial natriuretic peptide contributes to the antihypertensive action of many drugs

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 1, 2003, Pages 55-57

  Papadopoulos, C L ^a   Kokkas, B A ^a,b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

Antihypertensive drugs; Atrial natriuretic peptide

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELIPROLOL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; TERAZOSIN;

ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; ARTICLE; BLOOD LEVEL; ESSENTIAL HYPERTENSION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE SIZE; HEART VENTRICLE OVERLOAD; HUMAN;

EID: 0037275475     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190867     Document Type: Article

References (24)

1. Shields P., Glembotski C. (1989): Regulation of atrial natriuretic factor-secretion from neonatal rat primary atrial cultures by activators of protein kinases A and C. Biol. Chem. 264, 9322-9328
2. Hollenberg M., Plum J., Heering P., Kutkuthn H.B., Grabensee B (1991): Influence of betaxolol on renal function and atrial natriuretic peptide in essential hypertension. J. Hypertension 9, 819-824
3. Papadopoulos C.L., Kokkas B., Kotridis P., Kanonidis I., Kyriakou P., Poulntzas N., Kotoula M., Kouvelas D., Sabbatis S., Sakadamis G., Paradelis A. (1992): The long-term effect of β1-blocker bisoprolol on blood pressure and atrial natriuretic peptide plasma levels in hypertensive patients after. Arterial Hypertension (Greek) 1, 201-205
4. Papadopoulos C.L., Kokkas B., Kotridis P., Gitsios C., Sakadamis G., Kanonides I., Kotoula M., Paradelis A. (1995): The effect of β1-blocker bisoprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Intern. J. Angiology 4, 165-168
5. Hama J., Nagata S., Takenaka T., Kino S., Shimada M., Horiuchi M., Katori R. (1995): Atrial natriuretic peptide and antihypertensive action due to beta-blockade in essential hypertensive patients. Angiology 46, 511-516
6. Papadopoulos C..L., Kokkas B., Kotridis P., Karamousis M., Haldoupi A., Platis A., Dadous G. (1998): The effect of β1-blocker/β2-agonist celiprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Cardiovasc. Drugs Ther. 12, 345-346
7. Papadopoulos C.L., Kokkas B. (1998): ANP as a mediator of antihypertensive drug action. Rev. Clin. Pharmacol. Pharmacokin. (Greek) 12: 3-8
8. Papadopoulos C.L, Kokkas B., Anogiannakis G. (2000): Beta blockers and atrial natriuretic peptide (ANP) in hypertension. Intern. J. Immunopathol. Pharmacol. 13, 107-110
9. Prichard B., Cruickshank J., Graham B. (2001): Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Pressure 10, 366-386
10. Papadopoulos C.L., Kokkas B., Kotridis P., Gitsios C., Kanonidis I., Faitatziadis D., Pilis A., Theodoridis E., Paradelis A. (1995): Plasma atrial natriuretic peptide in essential hypertension after angiotensin coverting enzyme inhibition. Intern. J. Angiology 4, 44-45
11. Kotridis P., Kokkas B., Karamouzis M., Sakadamis G., Kanonidis I., Dadous G., Karadona C., Gouli O., Karadoumanis J., Papadopoulos P.C., Papadopoulos C.L. (2002): Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan. Blood Pressure 11, 91-94
12. Kokkas B., Kotridis P., Karamouzis M., Kanonidis I., Sakadamis G., Dadous G., Haritos S., Kyriakou P., Theodossiadis I., Papadopoulos P.C., Mirtsou-Fidani V., Papadopoulos C.L. (2002): Plasma atrial natriuretic peptide levels in essential hypertension after treatment with verapamil. Eur. J. Drug Metabol. Pharmacokin. 27, 45-48
13. Shamiss A, Peleg E, Rosenthal T, Rzra D. (1993): The role of atrial natriuretic peptide in the diuretic effect of Ca2+entry blockers. Eur.J. Pharmacol. 16, 113-117
14. Iwasaki T, Niwa A, Shinoda T, Ishihara M., Aizawa T., Yamada T. (1989): Effects of calcium antagonists and nitroglycerin on atrial natriuretic peptide in normal subjects and patients with essential hypertension. Angiology 40, 24-28
15. Shigematsu S, Yamada T, Aizawa T, Takasu N., Shimizu Z. (1992): Differential effects of nifedipine on plasma atrial natriuretic peptide in normal subjects and hypertensive patients. Angiology 43, 40-46
16. Rappelli A, Dessi-Fulgheri P, Bandiera F, et al. (1989): Increase of plasma atrial peptide levels after sublingual administration of nifedipine in essentially hypertensive patients. Int. J. Cardiol. 25 (Suppl. I), 25-28
17. Colantonio D, Casale R, Desiati P, et al. (1991): Short term effects of atenolol and nifedipine on atrial natriuretic peptide, plasma renin activity, and plasma aldosterone in patients with essential hypertension. J. Clin. Pharmacol. 31, 238-242
18. Cerasola G, Cottone S, Mangano M, D'Ignoro G., Pinto A., Carone M., (1988): Effects of felodipine on natriuresis, atrial natriuretic factor, the renin-angiotensin-aldosterone system, and blood pressure in essential hypertension. Clin. Ther. 10, 694-703
19. Lehnert H, Schmitz H, Preuss K, Kustner E., Krause O., Beyer J. (1993): Effects of nitrendipine on blood pressure, renin-angiotensin system and atrial natriuretic peptide in hypertensive type I diabetic patients. Horm. Metab. Res. 25, 24-28
20. Kotridis P., Kokkas B., Papadopoulos C.L., Karamouzis M., Salpigidis G., Karantina C., Karadoumanis J., Ginis T., Goulis O., Papadopoulos P.C., Vakalopoulos C., Dimitriadou A., Mirtsou-Fidani V., Papadopoulos C.L. (2002): Plasma atrial natriuretic peptide in essential hypertension after treatment with terazocin. 3rd Congress of the north Greek Society of Cardiology, Book of Abstracts, 8
21. Magga J., Kalliovalkama J., Romppanen H., Vuolteenaho O., Porsti I., Kahonen M., Tolvanen J., Ruskoaho H. (1999): Differential regulation of cardiac adrenomedullin and natriuretic peptide gene expression by AT1 receptor antagonism and ACE inhibition in normotensive and hypertensive rats. J. Hypertens. 17, 1543-1552
22. Yoshimoto T, Naruse M, Naruse K, Shionoya K., Tanaka M., Tanabe A., Hagiwara H., Hirose S., Muraki T., Demusa H. (1996): Angiotensin II-depended down regulation of vascular natriuretic peptide type C receptor gene expression in hypertensive rats. Endocrinology 137, 1102-1107
23. Yoshimoto T, Naruse M, Irie K, Tanabe A., Seki T., Tanaka M., Imaki T., Naruse K, Muraki T., Matsuda Y., Demura H. (1998): Beta-adrenergic antagonist propranolol potentiates hypertensive action of natriuretic peptides. Eur. J. Pharmacol. 12, 61-66
24. Yoshimoto T, Naruse M, Tanabe A, Naruse A., Naruse K., Seki T. Imaki T., Muraki T., Matsuda Y., Damura H. (1998): Potentiation of natriuretic peptide action by beta-adrenergic blocker carvedilol in hypertensive rats: a new antihypertensive mechanism. Endocrinology 139, 81-88.